已收盘 02-06 16:00:00 美东时间
+1.150
+3.33%
今日重点评级关注:康托·菲茨杰拉德:维持Wave Life Sciences Ltd."超配"评级,目标价从34美元升至41美元;Piper Sandler:维持Replimune Group"超配"评级,目标价从13美元升至14美元
02-06 16:52
今日重点评级关注:韦德布什:维持Replimune Group"跑赢大市"评级,目标价从18美元升至19美元;巴克莱:维持CytomX Therapeutics"超配"评级,目标价从8美元升至10美元
02-05 11:28
Needham analyst Tom Nikic reiterates Steven Madden (NASDAQ:SHOO) with a Buy and maintains $50 price target.
02-04 18:00
今日重点评级关注:摩根士丹利:维持Kyverna Therapeutics"超配"评级,目标价从20美元升至25美元;Maxim Group:维持Capricor Therapeutics"买入"评级,目标价从25美元升至50美元
2025-12-05 08:35
BTIG analyst Janine Stichter maintains Steven Madden (NASDAQ:SHOO) with a Buy and raises the price target from $43 to $50.
2025-12-04 19:11
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
2025-11-13 09:58
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价;Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:SHOO) with a Outperform and raises the price target from $43 to $45.
2025-11-06 21:04
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从3美元升至9美元;HC Wainwright & Co.:上调CervoMed评级至"买入",目标价从11美元升至25美元
2025-11-06 09:55
Steven Madden jumped ~7% as tariff-driven wholesale softness led to Q3 misses, but above-consensus Q4 EPS ($0.41–$0.46) and sales ($739.5M–$757.0M) guidance lifted the outlook.
2025-11-06 00:44